Unlike traditional therapies that target a single pathway, KBI-092 is engineered for a "two-pronged" attack on leukemia cells. Its therapeutic efficacy stems from the selective inhibition of two critical proteins:
The development of KBI-092 involves high-level collaboration within the biopharmaceutical ecosystem. , a leading global Contract Development and Manufacturing Organization (CDMO) , is frequently involved in scaling the production of complex biologics and small molecules for clinical trials. KBI-092
As of late 2025, KBI-092 has moved into the active clinical testing phase: Unlike traditional therapies that target a single pathway,
